Medical Training AIPsychedelic-Assisted Therapy Fundamentals
You'll be able to describe the mechanisms, screening criteria, and session-phase considerations relevant to psilocybin- and MDMA-assisted therapy for depression, PTSD, and anxiety.
What this track covers
This track covers the neurobiological basis of psychedelic-assisted therapy, current public protocol frameworks for psilocybin and MDMA in mood, trauma, and anxiety disorders, and the clinical workflow spanning screening, session support, and post-session integration. It's built for clinicians who need a working understanding of how these treatments are structured and where the safety considerations lie.
What you will practice
- Identify screening and exclusion criteria for psychedelic-assisted therapy candidates
- Distinguish the proposed mechanisms of action for psilocybin versus MDMA
- Recognize contraindications and drug interaction risks clinicians must rule out
- Walk through the phases of a therapy session, including preparation and support roles
- Apply integration-session principles to support patients after a dosing session
Simulator scenario
A patient with treatment-resistant depression presents for a pre-session screening visit, and the clinician must identify a contraindication before proceeding.
Board question topics
- Contraindications and drug interactions in psychedelic-assisted therapy
- Mechanisms of action of psilocybin and MDMA
- Session preparation and screening requirements
- Post-session integration and monitoring for adverse psychological reactions
Ask the tutor
The tutor only answers from licensed sources (FDA prescribing information, public guidelines and our own material) and says when it has none. Educational use only, never patient-specific advice.
Free during the beta. Sign in with your email, no password.
Start free